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Abstract 
Background: Most people with COVID-19 self-manage at home. However, the condition can 
deteriorate quickly and some may develop serious hypoxia with relatively few symptoms. Early 
identification of deterioration allows effective management with oxygen and steroids. 
Telemonitoring of symptoms and physiological signs may facilitate this.   
Objective: To design, implement and evaluate a telemonitoring system for people with COVID-19 
self-managing at home considered at significant risk of deterioration 
Methods: A multi-disciplinary team developed a telemonitoring protocol using a commercial 
platform to record symptoms, pulse oximetry and temperature. If symptoms or physiological 
measures breached targets, patients were alerted asking them to phone an ambulance (red) or for 
advice (amber). Patients attending COVID assessment centres, considered fit for discharge but at risk 
of deterioration, were shown how to use a pulse-oximeter and the monitoring system which they 
were to use twice daily for two weeks. Patients could interact by app, SMS or touch-tone phone. 
Written guidance on alerts was also provided.  
Following consent, patient data on telemonitoring usage and alerts were linked to data on service 
resource use. Subsequently, patients who had both used and not used the telemonitoring service, 
including those who had not followed advice to seek help, agreed to brief telephone interviews to 
explore their views on and how they had interacted with the telemonitoring system. Interviews were 
recorded and analysed thematically. Professionals involved in the implementation were sent an 
online questionnaire asking them about their perceptions of the service. 
Results: We investigated the first 116 patients who used the service.  Of these 71 (61%) submitted 
data, the remainder chose to self-monitor without electronic support. Of the 71 patients who 
submitted data, 35 received 151 alerts during their two-week observation. Sixty-seven ‘red’ alerts 
were for oxygen saturation (Sa02) levels ≤93% and 15 because they recorded severe breathlessness. 
Nineteen were admitted to hospital (average stay 3.4 days). Of the 45 who used written guidance 
alone, eight were admitted to hospital (average stay 5.3 days) and one died.  
Some patients who were advised to seek help did not do so, some because parameters improved on 
re-testing, others because they felt no worse than before. All patients found self-monitoring 
reassuring. Most professionals who used the system (n=11) found it easy to use and useful. Five 
professionals considered the system ‘very safe’, three thought it ‘could be safer’, and three wished 
more experience before deciding. Two felt SaO2 trigger thresholds were too high.  
Conclusions: Supported self-monitoring of patients with COVID-19 at home is reassuring to patients 
acceptable to clinicians and can detect important signs of deterioration.  Worryingly, some patients, 
because they felt well, occasionally ignored important signs of deterioration. It is important 
therefore to emphasise the importance of the early investigation and treatment of asymptomatic 
hypoxia at the time when patients are initiated and in the warning messages that are sent to 









It is well recognised that some patients affected with Coronavirus disease 2019 (COVID-19) who are 
initially not seriously unwell, will later develop severe disease requiring hospital admission. 
However, in most countries only the most seriously ill are admitted as hospitals quickly have become 
over-run [1-3].  
It has become clearer that early treatment of people with deteriorating disease is associated with 
better outcomes [4]. An analysis of early data from Jiangsu province in China suggested that early 
intervention reduced death rates (<1%) in comparison with Hubei Province (4.3%) where treatment 
was started later [5].  Likewise in South Korea, analysis of data showed that later presentation was 
associated with poorer outcomes, and countries such as Singapore which had a policy of early 
admission to hospital had a very low fatality rate [6,7]. Additionally delayed admission and level of 
presenting oxygen saturation (SaO2) in English patients has been shown to predict outcome with 
even relatively small reductions of SaO2 of 95% and below associated with increases in mortality [8].  
Early treatment is effective. Most of the lung injury in COVID-19 is due to inflammation [9] and in 
severely ill patients, the use of oxygen, steroids and novel anti-inflammatories, along with general 
supportive therapy have been shown to reduce death rate  or shorten admissions [10-13].  
The elderly and those with underlying medical conditions are at increased risk of deterioration [14] 
Other groups (healthcare staff, some ethnic minorities, and people with high body mass index) are 
particularly known to delay presentation which is associated with poorer outcomes [15]. 
The high death rate in the UK in those admitted too late for treatment to be effective, led to calls for 
more active monitoring both to detect early deterioration in these at risk groups and to encourage 
them to seek help [16].  
 
Detecting early deterioration 
Detecting deterioration can be challenging. Many patients present with pronounced arterial 
hypoxaemia yet without proportional signs of respiratory distress or sense of breathlessness. 
Dyspnoea was reported by only 18.7% of hospitalised patients in one series [17]. However, in some 
patients with significant lung disease, normal SaO2 can also be initially maintained by 
hyperventilation. It is important therefore to consider both symptoms of breathlessness and SaO2 to 
detect deterioration in COVID-19 [18]. Additionally, in some people with chronic lung disease 
borderline SaO2 is relatively frequent and may be less predictive in COVID-19 than the general 
population [19]. 
A recent Delphi exercise based in UK primary care, involving 72 clinicians, set out to develop an early 
warning score for deterioration in COVID-19 [20]. The authors suggested the following to be valuable 
in predicting deterioration : fast pulse rate, shortness of breath or respiratory rate, trajectory of 
breathlessness, pulse oximeter reading (with brief exercise test if appropriate) or symptoms 
suggestive of hypoxia, temperature or fever symptoms, duration of symptoms, muscle aches, new 
confusion, shielded list and known risk factors for poor outcome. They suggested a scoring system, 
the sensitivity and specificity of which is yet to be assessed.  
 
Many of the physiological parameters above are easily measured by low-cost devices, however it is 
important that these meet a quality standard (e.g. ISO 80601-2-61:2017 for pulse-oximeters). These 
are accurate within the range required to detect desaturation requiring hospitalisation. Many wrist-
worn oximeters and smartphone based oximeters are generally unreliable [21-23].  Raised 
respiratory rate, a strong predictor of poor outcomes, is more challenging to measure remotely 
[24,25], but, recently, pulse-oximeters which can estimate respiratory rate using the 
photoplethysmography (PPG) waveform and its amplitude variation have become available [26,27].  
 
Some countries have recommended and variably implemented the use of self-monitored pulse-
oximetry with daily nurse telephone follow-up in a ‘virtual ward’ arrangement [28,29]. At times of 
high community incidence though, when demand on all healthcare can rapidly rise, such intensive 
follow-up may be infeasible given that most patients will remain relatively well.  
 
Telemonitored supported self-management for COVID-19 
An alternative is to support self-management with a telemonitored approach.  Patients are 
requested to regularly record symptoms and physiological parameters and, if these suggest 
deterioration, automatic alerts to the patient recommend seeking advice or urgent care. The record 
is available for review by their clinicians. This is expected to facilitate early intervention and hence 
improve the patient’s eventual outcome.  
 
Telemonitoring has been adopted in several locations world-wide. As yet, there are no randomised 
controlled trials (RCT) of telemonitoring in COVID-19, although two are under way in the USA and 
Norway and scheduled to report later in 2021 [30,31]. However, several papers describing the early 
experience with telemonitoring systems in COVID [32,33]  and for facilitating early hospital discharge 
after COVID have been published [34-37].  All made use of pulse oximetry and some also measured 
temperature and recorded a variety of symptoms. The implementations employed a range of trigger 
alert levels for SaO2 (from <90% to <95%). The number of alerts varied across the studies, reflecting 
the trigger level settings and different populations being monitored (some were relatively young 
with few underlying conditions whereas in one some patients were receiving home oxygen) [38]. 
Overall telemonitoring was perceived as being helpful in detecting deterioration.  
 
Ideally, telemonitoring systems should work across a range of mobile phones, tablets and 
computers, and link to health service systems using open standards so that the service obtains 
timely robust data which are critical to managing workload. Telemonitoring systems that require 
patients to subscribe using their own smartphones or tablet PCs, could exclude more vulnerable 
older and poorer people who are less likely to have a smartphone or internet access [39]. 
 
There are potential risks to telemonitoring, such as over-reliance on physiological parameters by 
inexperienced clinicians, poor adherence to self-monitoring, failure to respond to alerts or faulty 
equipment. Implementations should be within an evaluative framework which examines impact on 
workload, utility to clinicians, usability, acceptability to patients and equity of access. In particular, 
rapid feedback of evaluation findings will be needed to modify and optimise the intervention. Below 
we describe the design and initial evaluation of a Scottish COVID home-monitoring system. 
 
Scottish COVID home-monitoring system  
In Scotland health services are provided free at point of care, paid for from general taxation. Early in 
the pandemic a COVID-19 clinical pathway was developed to manage patients according to their 
level of perceived risk (See table 1). Substantial numbers of people, with mild disease at first 
assessment but potentially at risk of future deterioration, are asked to remain at home and to call 
back only if symptoms are worsening.  However, some may delay or develop low oxygen saturation 
with few symptoms and as a result be admitted to hospital later than is optimal. Recognising the 
need for early detection of deterioration in COVID-19 in the late summer of 2020 the Scottish Chief 
Medical Officer called for systems to detect and manage this.   
 
Table 1: Risk stratification of suspected COVID-19 patients in the UK 
Risk stratification in the UK involves multiple layers of decision-making: 
1. People who consider themselves to have an immediately life-threatening illness can 
phone 999 for emergency ambulance, paramedic assessment and admission to hospital. 
2. People with less severe symptoms are steered to online advice (e.g. 
https://111.nhs.uk/covid-19), where a symptom checker directs people to self-
management advice if minimal or no symptoms, to call NHS111 if more significant 
symptoms, and to call an ambulance if life-threatening symptoms. 
3. Anyone can ring NHS111 for non-medical telephone advice and, depending on symptoms 
and their individual circumstances, a proportion are referred for GP telephone 
consultation or emergency assessment (calling an ambulance to attend the emergency 
room). 
4. GP telephone consultation may lead to advice only, face-to-face community assessment, 
or emergency assessment. Video consultations may also form part of a wider strategy of 
remote care for COVID-19 [17]. 
5. Face-to-face assessment may lead to advice to continue self-care at home, or to 
admission to hospital.   
 
Developing the monitoring system 
 Following the formation of an expert group (drawn from Scottish Government clinical advisors, 
primary and secondary care, the Scottish unscheduled care service (NHS24) and the Scottish 
Ambulance Service), a clinical protocol, based on current evidence and early international 
experience of telemonitoring, was developed. This protocol was subsequently approved by national 
professional groups. The system, based on a commercial platform (Inhealthcare® 
https://www.inhealthcare.co.uk/), provides twice daily reminders to record symptoms and collect 
data on pulse oximetry (at rest and post-exercise) and temperature over a 14 day period [40]. (See 
table 2) Patients can interact with the system by internet, app, SMS or by responding on their 
telephone keypad to pre-recorded questions.  
 
If responses suggest moderate deterioration, patients receive an automatic message advising them 
to phone 111 (the UK unscheduled care number) and their call is directed to general practitioners for 
initial telephone assessment. If symptoms or readings suggest a severe deterioration requiring 
possible hospitalization, patients are directed to call 999 (UK emergency number). (See appendix 1) 
 
















Setting triggers for symptom and physiological measurements 
Initial alert levels were based on expert clinical judgement and on extrapolation from other 
respiratory conditions and on national advice [41]. Trigger alerts were set for oxygen saturation, 
pulse, temperature and for worsening breathlessness and severe fatigue of recent onset (See table 3 
for triggers, rationale for these and advice given to clinicians on how to respond to these). It was 
expected that linkage of telemonitoring data to outcomes (reassessment, admission to hospital, 
need for respiratory support or ICU, death) would inform subsequent adjustment of alert thresholds. 
Saturation triggers were in part relative (a sudden fall from a higher level to 95% or 94% triggered an 
advice call) but a level of 93% or lower triggered an urgent warning. There was considerable debate 
about the trigger which occurred as a result of a fall to 95% from a higher level as there were 
concerns that this would create unnecessary workload. In the end concerns, particularly about 
underdiagnosis of hypoxia in people with pigmented skin, led to the adoption of this trigger. To test 
post exercise desaturation, patients whose resting saturation was 95% or above were asked to 
exercise (brisk walk or sit to stand) for one minute (or as long as they could) and remeasure their 
oxygen saturation. If this fell below 94% it triggered an alert.   Because of the difficulties interpreting 
readings from people who had existing significant respiratory conditions and long-term lower 
oxygen levels, this group was initially excluded.  
A symptom report of myalgia or cough resulted in an automatic suggestion to consider using 
symptom relieving medicine only and did not trigger an alert.  
  
Twice daily for 14 days 
 Symptom data:  
o Breathlessness – At rest, or on minimal activity  
o Cough 
o Fever 
o Severe recent onset fatigue  
o Myalgia (triggered advice on self-management only))  
 Physiological parameters: 
o Pulse rate, SpO2 (after 20 minutes seated and, if physically 
able, after 1 minute walking, or sitting to stand), 
temperature  
 
Table 3: Alert triggers set for the Scottish telemonitoring system and suggested response. 
Symptom/ 
physiological reading 
recorded by patient 
Advice to patient Rationale Considerations for clinician 
Breathless difficulty 
speaking 




illness, but may be 
anxiety 
Normally managed by the Scottish 
Ambulance Service   
Worsening breathless 
Breathless on minimal 
exertion 
You seem to be 
getting more 
breathless please 
phone 111** for 
advice 
Worsening 
breathlessness is an 
early sign of severe 
COVID.  
Speak with patient to confirm decline, 
does patient sound breathless at rest, are 
they drinking and eating.  If patient has 
oximeter and saturation is ≥94% after 1 
min exercise and otherwise OK consider 
continuing observation with safety-
netting.  
 
If patient does not have functioning 
oximeter consider seeing to measure 
saturation and assess respiratory rate 
Severe 
tiredness/exhaustion 
in last 24 hours. (only 
triggers call to 111 if 
no pulse oximeter 
available) 
Sudden onset of 
tiredness can 
suggest a 
deterioration in your 
condition please 
phone 111 for 
advice 
Severe tiredness is 
associated with 
hypoxia 
Speak with patient to confirm decline, 
review oxygen saturation if available, have 
they become more breathless, are they 
drinking and eating, is there evidence of 
secondary infection?  Consider reviewing  
to check oxygen saturation if they do not 
have a functioning oximeter 
Oxygen saturation 
<94% 
Your oxygen level is 






Normally managed by the Scottish 
Ambulance Service   
Oxygen saturation 
94% or 95% at rest 
(only triggers alert if 
previously higher 
than 95%) 
Your oxygen level is 
a little low please 
phone 111 for 
advice 
May be important if 





Speak to patient to confirm general status, 
check for increasing breathlessness. If 
level has fallen from previously high level, 
particularly in the presence of increased 
breathlessness,  suggests  worrying 
deterioration and therefore consideration 
of further assessment 
Resting pulse rate 
>100 bpm 
Your pulse rate is 
higher than 
expected, please 
repeat after resting 
and if still over 100 




serious illness.  
Speak to patient to confirm general status, 
increasing breathlessness, Compare with 
previous heart rate measures if relatively 
stable and close to 100 consider 
observing. If rising, consider worsening 
COVID, pulmonary embolus or arrythmia 
(atrial fibrillation is a common 
complication of COVID-19 ) 
Persistent fever of > 
38oC for more than 5 
days 
Your temperature 
has been high for 5 
days or more please 





Increased risk of 
serious outcome.  
Speak to patient to confirm general status, 
increasing breathlessness, chest pain, 
coloured spit, symptoms of other 
infections like UTI. Consider further 
examination/investigation 
One off fever of > 
38.5 oC 
Your temperature is 
higher than 
expected, please 
phone 111 for 
advice. 
Raises concerns of 
severe illness 
Speak to patient to confirm general status, 
increasing breathlessness, chest pain, 
coloured spit, symptoms of other 
infections like UTI. Consider further 
examination/investigation  
*999 is UK emergency ambulance number. **111 is for telephone medical advice and triage 
Selecting patients for monitoring  
Initially in Scotland the system was offered to people attending primary care COVID Assessment 
Centres in person after a physical examination, and in the remote and rural setting to patients 
admitted briefly but considered fit for discharge and self-monitoring.  However, it was expected that 
initiation from emergency departments, general practice or remotely, following video assessment, 
would also be possible.  People considered at higher risk of deterioration, (but with symptoms and 
physiological signs below the threshold for hospital admission) were offered monitoring.  Although 
algorithm-based calculators such as COVID-AGE [42]  were considered, the final decision on whom 
was considered suitable for monitoring was left to the assessing doctors usually based on age, 
underlying illness, clinical condition, and capacity to manage the system (see figure 1). Patients were 
given a pulse oximeter and shown how to use it. They were told not to wait for requests for data if 
they felt they were deteriorating but to phone immediately for advice. It was made clear to patients 
that the system was based on self-monitoring, that there was no systematic review of alerts and that 
it was their responsibility to seek help if symptoms or physiological measures suggested this. 
Patients were also given written guidance on using the device and on what to do should trigger 
levels be breached and could opt to self-monitor without telemonitored support. 
A full description of the system, including information for clinicians and patients, governance and 
technical information is available online. [43,44]    
Initial experience with the system 
Two Scottish health boards, one rural and one mixed rural/urban, took part in the pilot 
implementation. Levels of COVID-19 had begun to fall in the rural area, however, the mixed 
urban/rural area still had high levels of transmission. The following describes the experience of the 
first 116 patients.  
Methods 
Completion of the UKRI/MRC/NHS RHA decision tool (15.4.21) confirmed that this evaluation ‘would 
not be considered research by the NHS’ and therefore did not require ethical approval. All patients 
who took up the offer of telemonitoring gave permission for their data to be used to evaluate and 
improve the service. Data were extracted from the Inhealthcare system and linked to service 
resource use by the NHS Board team. The clinical team subsequently obtained verbal consent for a 
follow-up telephone interview with sample of patients selected on the basis of age, sex, whether or 
not they had used the system, received alerts, their response to any alerts, and subsequent resource 
use.   
Interviews were carried out by HA, who was not involved in the design or implementation of the 
system. Caldicott Guardian approval was granted by NHS Highland (15.4.21) for sharing data related 
to interviewing their patients.  This was not required for NHS Lanarkshire as HA is an employee.  All 
interviews were conducted by telephone (see appendix for topic guide), digitally-recorded and 
analysed thematically.  
Professionals involved in the implementation were sent a link to an on-line questionnaire (see 
appendix) asking them about their perceptions of the safety and utility of the system, ease of 
onboarding and explaining the system to patients, the professional user interface, the 
appropriateness of the triggers and suggestions for improvement. 
Results 
System and resource use data 
Of the first 116 patients who were given oximeters and expressed interest in using the system, 56% 
chose to use SMS, 28% an app, 6% web portal and 5% automated call-back with touch tone phone. 
(5% missing data).  Of those who signed up 71 (61%) submitted some data. The remaining 45 (39%) 
could choose to self-monitor without telemonitored support. Table 4 shows the demography of the 
participants. 
Table 4. Demography of the participating patients. There were 111 patients from Lanarkshire and 6 
from Highland. 
Cohort n=116 Those who submitted 
readings (n=71) 
Those who did not submit 
readings (n=45) 
Sex 40 women, 31 men 20 women, 25 men 
Average age (range) 51.3 years (24-94) 54.0 years (25-87) 
 
The alert history and their subsequent service contacts are summarised in table 5. Of the 71 patients 
who sent data, 35 patients alerted at some point, logging 151 alerts. Of these, 28 patients had ‘red’ 
emergency alerts suggesting they call an ambulance and 6 people received only ‘amber’ advice-only 
alerts. The same episode could trigger several alerts for different parameters or symptoms.  Sixty-
seven red alerts were triggered by oxygen saturation levels lower than ≤93% and 15 by responding 
that they were “unable to speak in sentences because of breathlessness”.  Table 5 shows how these 
patients subsequently used health services. There was one death. However, this occurred two days 
after assessment in a patient who had not used telemonitored support.  
  
Table 5. Alerts issued and subsequent health service use. 
Cohort n=116 Those who submitted 
readings (n=71) 
Those who did not 
submit readings (n=45) 
Total no. amber alerts 69 N/A 
Total  no. red alerts 82 N/A 
No. people who received at least one amber 
but no red alerts 
7 (10%) N/A 
No. people who received at least one red 
alert 
28 (39%) N/A 
No. who phoned 111 (out of hours primary 
care) 
18 (258%) 11 (24%) 
No. who contacted COVID assessment 
centre 
8 (11%) 4 (8%) 
No. who attended emergency department 19 (27%) 10 (22%) 
No. admitted to hospital 19  (27%) 8 (17%) 
Average length of hospital stay ( days) 3.4 5.3a 
Deaths  1 
a One patient stayed in hospital for 14 days, increasing the average length of stay from 4 to 5.3 days.  
A single episode could generate several alerts and several contacts, for example a patient with breathlessness 
could also generate alerts for low SaO2, high pulse and temperature.   The patient could contact NHS24 be 
directed to the COVID assessment centre, then on for assessment in the emergency department before 
admission to hospital. Some were admitted directly to hospital via ambulance while most passed through the 
emergency department. 
 
There were several instances where patients ignored red alerts to seek advice.  Figure two shows the 
case flow of several such patients, and this is discussed further in the interview analysis. 
Patients had been encouraged not to wait for a request for data if they thought their condition was 
worsening. Eight patients who sent data, but had not received alerts had a total of four ED 
attendances, four OOH contacts, three COVID-19 assessment centre contacts and four hospital 
admissions (average length of stay 3 days).  
Contact rates and hospital admission rates were similar for people who did and did not use the 
telemonitoring support.   
Patient interviews 
Fourteen patients agreed to participate in a brief telephone interview (see table 6 for patient 
characteristics) to explore their experience of using the system, determine why some had not 
followed advice to seek help and why others had chosen not to send data.  These were conducted 
between 5 and 8 weeks after signing up for remote monitoring and lasted an average of 6.5 minutes.  
  
Table 6. Characteristics of interviewees. 






(length of stay) 
1 31 Female SMS text 2 red, 1 amber No No 
2 49 Female App 5 red, 1 amber No No 
3 a 47 Male SMS text 2 red No No 
4 b 75 Female SMS text 1 red No No 
5 66 Male SMS text 8 red, 4 amber Yes Yes (1 day) 
6 54 Female SMS text 1 red, 3 amber Yes Yes (< 1 days) 
7 b 25 Male SMS text 1 red Yes No 
8 47 Male SMS text 7 amber Yes No 
9 55 Male App 1 amber Yes Yes (<1 day 
days) 
10 36 Female SMS text 1 amber Yes No 
11 b 92 Female App None N/A No 
12 41 Male SMS text No readingsc N/A  No 
13 70 Male App No readingsc N/A No 
14 50 Male SMS text No readingsc N/A No 
a Patient interviewed, but spouse did monitoring 
b Interviewed carer/relative who was responsible for remote monitoring 
c Self monitored but did not submit data 
  
All 11 people interviewed who had used the remote monitoring system described it as ‘easy’ or 
‘straightforward’.  Interestingly, in four cases the monitoring had been done on behalf of the person 
with COVID-19, either because the patient was unable to (due to dementia or special needs) or 
because someone was better able to engage with the technology on their behalf.  For this group, 
being less digitally literate was not necessarily a barrier to remote health monitoring.  Although 
three of the interviewees had not uploaded readings, they had used the pulse oximeter and felt it 
had been ‘a good idea’ or ‘a comfort’ to them.  All 14 people interviewed said remote monitoring 
provided reassurance or ‘stopped you worrying’ and endorsed its use by others in the same position.  
However, not everyone monitored for the full two weeks, one saying they ‘just got scunnered [fed-
up] with it’. 
Four interviewees had received alerts from the system but elected not to follow the advice received.  
Two explained that instead of calling 111 or 999 immediately they had waited 10 minutes, taken 
their readings again, and found they had gone ‘back to normal’.  One added there was ‘nothing to 
panic about’ and the other went on to say, ‘I knew I wasn’t really needing help’.  This was also the 
prime motivation for the third person (a former healthcare employee) who did not follow the advice 
received; ‘I know myself because I felt OK’.  Two of those not following the advice felt the healthcare 
resources should have been left for ‘somebody else that does need it’.  The decision not to respond 
to alerts for the fourth person was made by her niece who was doing the monitoring.  She explained 
that some were triggered by submitting the wrong readings, whilst others were when her aunt was 
‘really not good’.  The niece was clear that on the night after being assessed, ‘she wouldn’t have 
wanted it anyway, so I didn’t bother’ and they had agreed she would wait to get better. 
Although it was more difficult to make contact with those who had chosen not to submit data, three 
agree to an interview.  They all valued having the pulse oximeter and reported that they had used it, 
either twice a day, as directed, or more often e.g., ‘every couple of hours’.  One was still using it six 
weeks after being given it, and another had found it so useful they had passed it on to other family 
members who had tested positive for COVID-19.   
In terms of the reasons for not uploading monitoring results to the system, one person had clearly 
misunderstood that they were supposed to do so.  They reported that they were ‘meant to tell the 
doctor’ and had not been asked to submit results via a mobile, computer or landline phone. They 
demonstrated a facility with taking their readings during the interview.  The other two who had not 
submitted results said they had felt too unwell to engage with it.  One valued ‘having the meter 
there’ because ‘you knew the safe limits and it was a comfort knowing you were within those safe 
limits’ and the other referred to the trigger levels in the leaflet and said, ‘if I got to that level, I’d 
obviously have to call the emergency services’.   
Many interviewees described how much they appreciated having knowledge of what their 
monitoring levels should be following their COVID-19 diagnosis.  One said it was ‘an eye opener’ 
because ‘this disease is going after the respiratory system and that’s the one we need to watch’.  
Another who was ‘not a medical person’ found it interesting ‘to understand how things change when 
you walk about and sit down a wee bit out of breath’.  A third had been keen to engage after hearing 
news about pulse oximeters ‘being able to indicate that people were beginning to become more 
unwell without feeling it’ and one suffering from fatigue seven weeks later still checked their levels 
after being active. 
Curiously, one interviewee who hadn’t responded to their alerts suggested others should behave 
differently, saying ‘I would like to think they would do what it says and respond’.  Another said that 
the reassurance they got from monitoring meant they ‘didn’t phone NHS24 [111 the unscheduled 
care service] as much as maybe without it [they] might have’ and a third felt more generally that it 
would ‘save a lot of people from phoning 111 or 999 when really it wasn’t necessary’. 
Professionals’ views 
Fourteen professionals responded to the on-line survey; six doctors, six nurses, one administrator 
and one who did not give their role.  Three had not used the remote monitoring system, but one of 
them commented ‘it’s a great idea’ and explained the only reason they’d not used it was because 
they had mainly seen children rather than adults.  One of those who had not used the system did not 
consider the system was useful or safe.  
 
Of the 11 professionals who had used COVID-19 remote monitoring, six had found it ‘fairly’ and five 
‘very’ useful.  Five thought it was ‘very safe’, three that it ‘could be safer’, two were not sure and 
one felt it was too soon to say.  All who had initiated patients on the system found it very (n=5) or 
fairly (n=5) easy, and the three who had used the professional user interface thought it was easy.  It 
was suggested this could be visually simpler, and that permission to individualise parameters would 
be an advantage.   
 
Seven felt the trigger levels were about right, two weren’t sure and two said that alerts were 
triggered too early.  One of these explained that the information around the levels may need to be 
expanded and the other felt that the oxygen saturation level at which calling an ambulance was 
recommended was too high for many people (and would result in too many alerts).  In the additional 
comments section, another felt the number of alerts was ‘slightly annoying’ and a third felt the fact 
this was self-monitoring should be stressed to patients and relatives. 
 
National Implementation 
Implementing new systems in the midst of a pandemic is very challenging. This solution faced 
challenges at local levels in terms of information governance and IT compatibility issues which took 
much longer than expected to resolve.  Despite being relatively small country, Scotland is divided 
into fourteen health boards all with their own governance and IT teams across Scotland which were 
very stretched with many competing priorities. The solution went live as the peak of Scotland’s 
second wave had passed and so some areas did not feel the same pressure to prioritise this solution. 
At the time of writing four health boards have used the system and further four are preparing to set 
up the infrastructure to be available in the event of a third wave following ending of restrictions or in 
the event of a new variant emerging. Other boards wanted to see the result of the pilot before 
committing to it.  
 
Discussion 
In periods where there is high community transmission of COVID-19, health services run the risk of 
being overwhelmed. It is sensible, therefore, that people with milder illness are managed at home. 
However, given that some in this group will deteriorate, it is important that deterioration is detected 
early enough to allow effective hospital treatment. Self-monitoring of symptoms and oxygen 
saturation provides a means of achieving this.  
 
Some patients are more likely to deteriorate than others and selection is therefore important, 
particularly where resources are constrained. Those ‘higher risk’ patients selected for home 
monitoring in the Scottish supported home monitoring system had a relatively high hospitalisation 
rate suggesting that the selection process was relatively effective.  
 
In general, those patients that opted to use it found supported self-monitoring easy to undertake. It 
was designed to be accessible, offering both digital and non-digital means of communication. It was 
interesting that most people opted to interact with the system by SMS possibly reflecting an older 
age group. However, marketing research shows that people are highly likely to read and respond to 
SMS, more so than other media, and an advantage is that it will work with all kinds of mobile phone 
[45]. 
 
Clinicians also found the system relatively simple to initiate and were largely convinced of its 
benefits. However, 39% of patients offered the system opted to self-monitor without assistance or 
not to monitor at all.  Patients were introduced to the telemonitoring system at a time when they 
were variably ill (some felt too ill to use it fully) and when clinical staff were under great pressure. 
However, everyone interviewed endorsed the system and those interviewed who had not submitted 
readings had self-monitored with pulse oximetry. Although patients were also given written 
information, possibly an approach the following day by phone from a dedicated member of a 
monitoring team would have allowed a better explanation of the system and encouraged take-up.  
 
Although the patients in our case study who opted for telemonitoring were very positive about the 
feeling of reassurance it gave them, we found that some ignored serious automatic warnings of 
deterioration even after receiving clear instructions to seek help.  When patients were questioned 
why they did not respond to such warnings, some explained that parameters improved on repeating 
after a few minutes or that they had miskeyed a response. However, worryingly, others stated that 
as they felt fine they did not feel the need to call, clearly not realising that asymptomatic hypoxia 
was potentially dangerous. Clinicians, therefore, need to strongly emphasise this danger when on-
boarding patients and it should be reinforced by written materials and in the warning messages.  
 
Nonetheless in many cases where deterioration was identified, this appears to have resulted in 
appropriate assessment either at a local COVID assessment centre, emergency department or a 
direct hospital admission. Several people contacted support services about alerts which did not 
result in change of treatment although this was relatively infrequent. Those who had oximeters but 
were not transmitting data had had a similar number of contacts. We do not know if this group 
differed in terms of the severity of their illness at presentation.  Interviews suggest that the 
reassurance provided by monitoring may have prevented some contacts which might otherwise 
have occurred. In other telemonitored respiratory conditions patients have said that such 
reassurance allowed them to self-manage rather than call for advice.[46] COVID-19 remote 
monitoring was not designed to alter workload, but the results of the ongoing RCTs will hopefully 
inform whether or not it has an impact on both outcomes and workload. The patients interviewed all 
endorsed its usefulness to them, whether or not they uploaded their monitoring readings, and this 
early evaluation adds to the emerging evidence base [47]. 
 
As a result of this pilot, messaging to patients has changed emphasising the need to contact services 
if saturations are low even if they feel well and likewise, if symptoms raise alerts, to call even if 
saturations appear normal.  
 
CONCLUSION 
Supported self-monitoring of patients with COVID-19 at home is reassuring to patients acceptable to 
clinicians and can detect important signs of deterioration.  Worryingly, some patients, because they 
felt well, occasionally ignored important signs of deterioration. It is important therefore to 
emphasise the importance of the early investigation and treatment of asymptomatic hypoxia at the 
time when patients are initiated and in the warning messages that are sent to patients.   
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